Vera Bradley, Inc. (VRA) Analysts See $-0.10 EPS; Curis (CRIS)’s Sentiment Is 0.86

Vera Bradley, Inc. (NASDAQ:VRA) Logo

Curis Inc (CRIS) investors sentiment decreased to 0.86 in Q1 2018. It’s down -0.73, from 1.59 in 2017Q4. The ratio has worsened, as 30 funds increased or started new positions, while 35 sold and reduced their holdings in Curis Inc. The funds in our database now own: 62.11 million shares, down from 75.55 million shares in 2017Q4. Also, the number of funds holding Curis Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 10 Reduced: 25 Increased: 16 New Position: 14.

Analysts expect Vera Bradley, Inc. (NASDAQ:VRA) to report $-0.10 EPS on June, 6 before the open.They anticipate $0.01 EPS change or 11.11% from last quarter’s $-0.09 EPS. After having $0.33 EPS previously, Vera Bradley, Inc.’s analysts see -130.30% EPS growth. The stock increased 0.26% or $0.03 during the last trading session, reaching $11.6. About 201,820 shares traded. Vera Bradley, Inc. (NASDAQ:VRA) has risen 39.27% since May 31, 2017 and is uptrending. It has outperformed by 26.70% the S&P500.

The stock decreased 0.59% or $0.01 during the last trading session, reaching $2.28. About 769,299 shares traded or 77.24% up from the average. Curis, Inc. (CRIS) has declined 73.52% since May 31, 2017 and is downtrending. It has underperformed by 86.09% the S&P500.

Another recent and important Curis, Inc. (NASDAQ:CRIS) news was published by Benzinga.com which published an article titled: “30 Stocks Moving In Wednesday’s Mid-Day Session” on May 30, 2018.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $377.63 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on August, 2. They expect $-0.09 EPS, up 10.00% or $0.01 from last year’s $-0.1 per share. After $-0.07 actual EPS reported by Curis, Inc. for the previous quarter, Wall Street now forecasts 28.57% negative EPS growth.

Sio Capital Management Llc holds 0.33% of its portfolio in Curis, Inc. for 834,551 shares. Gsa Capital Partners Llp owns 1.91 million shares or 0.07% of their US portfolio. Moreover, First Eagle Investment Management Llc has 0.04% invested in the company for 24.90 million shares. The New York-based Focused Wealth Management Inc has invested 0.04% in the stock. Bain Capital Public Equity Management Llc, a Massachusetts-based fund reported 576,591 shares.

Vera Bradley, Inc., together with its subsidiaries, designs, makes, and sells women's handbags, luggage and travel items, fashion and home accessories, and gifts. The company has market cap of $413.37 million. The firm offers totes, crossbodies, satchels, clutches, backpacks, baby, and lunch bags; accessories, inclduing wallets, wristlets, eyeglass cases, jewelry, scarves, and various technology accessories; and travel products, such as rolling luggage, cosmetics, and travel and packing accessories, as well as travel bags comprising duffel and weekend bags. It has a 61.05 P/E ratio. It also provides home products consisting of mugs and tumblers, as well as textiles products, such as throw blankets, beach towels, comforters, and wellness and beauty products; offers apparel/footwear, stationery, merchandising, and gift card products; and licenses its products.

More recent Vera Bradley, Inc. (NASDAQ:VRA) news were published by: Globenewswire.com which released: “Vera Bradley Announces Reporting Date for Fiscal Year 2019 First Quarter Results” on May 17, 2018. Also Nasdaq.com published the news titled: “Vera Bradley to Present at Robert W. Baird 2018 Global Consumer, Technology & Services Conference in NYC” on May 21, 2018. Globenewswire.com‘s news article titled: “Recent Analysis Shows ABM Industries, Waddell & Reed Financial, South State, Vera Bradley, Healthcare Trust of …” with publication date: May 23, 2018 was also an interesting one.

Investors sentiment decreased to 1.02 in 2018 Q1. Its down 0.31, from 1.33 in 2017Q4. It worsened, as 15 investors sold Vera Bradley, Inc. shares while 34 reduced holdings. 18 funds opened positions while 32 raised stakes. 22.06 million shares or 2.95% more from 21.43 million shares in 2017Q4 were reported. Shell Asset Management invested in 0.02% or 99,349 shares. Matarin Limited Liability Company owns 434,719 shares for 0% of their portfolio. The Ontario – Canada-based Manufacturers Life Insurance Communication The has invested 0% in Vera Bradley, Inc. (NASDAQ:VRA). Assetmark invested in 0% or 103 shares. Spark Investment Management Limited Liability holds 0.02% of its portfolio in Vera Bradley, Inc. (NASDAQ:VRA) for 26,400 shares. 5,975 are held by State Of Alaska Department Of Revenue. Mackay Shields Ltd Llc owns 11,000 shares for 0% of their portfolio. Alliancebernstein Lp has invested 0% in Vera Bradley, Inc. (NASDAQ:VRA). Invesco Ltd reported 106,810 shares. Gotham Asset Management owns 0% invested in Vera Bradley, Inc. (NASDAQ:VRA) for 18,566 shares. D E Shaw holds 0% of its portfolio in Vera Bradley, Inc. (NASDAQ:VRA) for 200,261 shares. Meeder Asset accumulated 300 shares. 1,814 are owned by Ameritas Investment Ptnrs Inc. Peak6 Investments L P accumulated 70,183 shares or 0% of the stock. Millennium Mngmt Llc reported 51,223 shares.

Among 8 analysts covering Vera Bradley (NASDAQ:VRA), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Vera Bradley had 29 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Wednesday, August 30. On Monday, August 28 the stock rating was maintained by FBR Capital with “Buy”. As per Tuesday, October 3, the company rating was maintained by Robert W. Baird. The stock of Vera Bradley, Inc. (NASDAQ:VRA) earned “Hold” rating by KeyBanc Capital Markets on Thursday, August 24. The rating was maintained by Robert W. Baird on Wednesday, August 30 with “Hold”. The stock of Vera Bradley, Inc. (NASDAQ:VRA) has “Hold” rating given on Wednesday, March 14 by Cowen & Co. The rating was downgraded by Jefferies to “Hold” on Tuesday, August 18. The rating was maintained by Robert W. Baird with “Hold” on Wednesday, December 6. The stock of Vera Bradley, Inc. (NASDAQ:VRA) has “Market Perform” rating given on Thursday, September 3 by Telsey Advisory Group. Cowen & Co maintained Vera Bradley, Inc. (NASDAQ:VRA) on Thursday, September 3 with “Underperform” rating.

Vera Bradley, Inc. (NASDAQ:VRA) Institutional Positions Chart